Abstract
Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations. For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukaemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation. The drug is also indicated for Ph+ acute lymphoblastic leukaemia (ALL). Ponatinib was temporarily suspended in 2013 for the occurrence of cardiovascular thrombotic events. Since then, different investigators analyzed baseline characteristics of patient candidates for ponatinib, especially cardiovascular profile, in order to describe general management recommendations in this setting.
In this review, clinical trials data about the use of ponatinib in CML and Ph+ ALL patients will be discussed. It will be focused also about the safety and tolerability profile of the drug and future perspectives of employment.
Keywords: Chronic myeloid leukemia, Ph+ acute lymphoblastic leukemia, ponatinib, T315I mutation, cardiovascular events, PACE trial, EPIC trial.
Current Cancer Drug Targets
Title:Ponatinib: A Review of Efficacy and Safety
Volume: 18 Issue: 9
Author(s): Fulvio Massaro, Matteo Molica and Massimo Breccia*
Affiliation:
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome,Italy
Keywords: Chronic myeloid leukemia, Ph+ acute lymphoblastic leukemia, ponatinib, T315I mutation, cardiovascular events, PACE trial, EPIC trial.
Abstract: Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations. For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukaemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation. The drug is also indicated for Ph+ acute lymphoblastic leukaemia (ALL). Ponatinib was temporarily suspended in 2013 for the occurrence of cardiovascular thrombotic events. Since then, different investigators analyzed baseline characteristics of patient candidates for ponatinib, especially cardiovascular profile, in order to describe general management recommendations in this setting.
In this review, clinical trials data about the use of ponatinib in CML and Ph+ ALL patients will be discussed. It will be focused also about the safety and tolerability profile of the drug and future perspectives of employment.
Export Options
About this article
Cite this article as:
Massaro Fulvio, Molica Matteo and Breccia Massimo*, Ponatinib: A Review of Efficacy and Safety, Current Cancer Drug Targets 2018; 18 (9) . https://dx.doi.org/10.2174/1568009617666171002142659
DOI https://dx.doi.org/10.2174/1568009617666171002142659 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring the Chemical Space of P-Glycoprotein Interacting Compounds
Mini-Reviews in Medicinal Chemistry Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Chalcones in Cancer: Understanding their Role in Terms of QSAR. II Part
Mini-Reviews in Medicinal Chemistry Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Origin of Lentivirus Research: Maedi-Visna Virus
Current HIV Research Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients
Current Pharmaceutical Design Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets The “Tilted Peptide Theory” Links Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides
Protein & Peptide Letters Precision Mechanics with Multifunctional Tools: How HnRNP K and HnRNPs E1/E2 Contribute to Post-Transcriptional Control of Gene Expression in Hematopoiesis
Current Protein & Peptide Science Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ovarian Toxicity: From Environmental Exposure to Chemotherapy
Current Pharmaceutical Design Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets